STABILITY INDICATING LIQUID CHROMATOGRAPHIC METHOD FOR THE QUANTITATIVE DETERMINATION OF RUFINAMIDE IN PHARMACEUTICAL DOSAGE FORMS by ANNAPURNA, M MATHRUSRI et al.
Mathrusri et al                                       Journal of Drug Delivery & Therapeutics; 2012, 2(4), 167-174    167 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
RESEARCH ARTICLE 
STABILITY INDICATING LIQUID CHROMATOGRAPHIC METHOD FOR THE 
QUANTITATIVE DETERMINATION OF RUFINAMIDE IN PHARMACEUTICAL 
DOSAGE FORMS 
M Mathrusri Annapurna*, B Sai Pavan Kumar, SVS Goutam and L Srinivas  
Department of Pharmaceutical Analysis & Quality Assurance, 
GITAM Institute of Pharmacy, GITAM University, Visakhapatnam-530045, India 
*Corresponding author’s E mail: mathrusri2000@yahoo.com Tel: 91-9985654603 
Received 13 June 2012; Review Completed 14 July 2012; Accepted 14 July 2012, Available online 15 July 2012 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
Rufinamide is chemically known  as 1- [(2, 6-
difluorophenyl) methyl]-1H-1,2,3-triazole-4 carboxamide 
with molecular formula C10H8F2N4O and molecular weight 
238.19 g/mol as shown in Figure 1. Rufinamide is an 
antiepileptic drug approved by the US Food and Drug 
Administration as adjunctive treatment of seizures 
associated with Lennox-Gastaut syndrome in children 4 
years and older and adults. Lennox-Gastaut syndrome 
consists of a variety of treatment-resistant seizures and is 
most common among paediatric patients 
1
. The mechanism 
of action of Rufinamide is unknown but it is presumed to 
involve stabilizat ion of the sodium channel inactive state, 
effectively keep ing the ion channels closed. It is believed 
to prolong the refractory period of voltage-dependent 
sodium channels, making neurons less likely to fire 
2
.  
 
Figure 1: Chemical Structure of Rufinamide  
Very few methods are reported in the literature regarding 
the clinical studies and no stability indicating method is 
available in the official compendia using HPLC for 
analysing Rufinamide in dosage forms. Analytical methods 
for Rufinamide from pharmaceutical dosage form should 
be developed and validated. To date, all analytical methods 
described in literature for the determination of Rufinamide 
in biological fluids involve liquid chromatography 3-7 and 
liquid chromatography–mass spectrometry methods 8-9. 
Quality control of pharmaceutical products requires 
identification and quantification of the active ingredient 
and its impurities for safety and efficacy reasons. 
Impurit ies and potential degradation products that may 
exist in medicines can change the chemical, 
pharmacological and toxico logical properties of the 
product. Since pharmacopoeias do not describe a suitable 
method for the determination of Rufinamide in  
pharmaceutical formulations, in the present work we 
developed simple, rap id and accurate reverse phase liquid 
chromatographic method for the determination of 
Rufinamide tablets as an alternative method. Apart from 
this, it can be used for assays of Rufinamide in biological 
flu ids or in pharmacokinetic investigations.  
MATERIALS AND METHODS 
Chemicals and Reagents  
Rufinamide standard (purity ≥ 98.0%) was obtained from 
Eisai Pharmaceuticals (Visakhapatnam, India).  Methanol 
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(HPLC grade), sodium hydroxide (NaOH) and 
hydrochloric acid (HCl) and hydrogen peroxide (H2O2) 
were purchased from Merck (India).  
Rufinamide is available as tablets with brand names 
Pr
BANZEL
™ ® 
as tablets (Label claim: 200 and 400 mg) 
and BANZEL
®
 as tablets (Label claim: 200 and 400 mg) 
as well as oral suspension (Label claim: 40 mg/mL) . All 
chemicals were of analytical grade and used as received.   
Instrumentation      
Chromatographic separation was achieved by using a 
Shimadzu Model CBM -20A/20 Alite HPLC system, 
equipped with SPD M20A prominence photodiode array 
detector (250 mm × 4.6 mm, 5 µm particle size) 
maintained at 25 ºC.  
Chromatographic Conditions  
Isocratic elution was performed using methanol and water 
(52:48, V/V) with flow rate 1.0 mL/min. 20 µL of sample 
was injected into the HPLC system.  
Preparation of Rufinamide Stock Solution 
Rufinamide stock solution (1000 μg/mL) was prepared by 
accurately weighing 25 mg of Rufinamide in a 25 mL 
amber volumetric flask and making up to volume with  
mobile phase. Working solutions for HPLC injections 
were prepared on a daily basis from the stock solution in a 
solvent mixture of methanol and water (52:48, V/V) 
(mobile phase). Solutions were filtered through a 0.45 μm 
membrane filter prior to injection. 
Preparation of Sample Solutions  
Twenty tablets from each brand (
Pr
BANZEL
™ ® 
and 
BANZEL
®
) were procured, weighed and crushed to a fine 
powder. Powder equivalent to 25 mg Rufinamide was 
accurately weighed into a 25 ml volumetric flask and made 
up to volume with mobile phase. The contents of the 
volumetric flask were sonicated for 30 min to enable 
complete dissolution of Rufinamide. The solution was 
filtered and the filtrate was diluted with mobile phase. 20 
μL of these solutions were injected into the system and the 
peak area was recorded from the respective chromatogram.  
Forced Degradation Studies/Specificity  
The study was intended to ensure the effective separation 
of Rufinamide and its degradation peaks of formulat ion 
ingredients at the retention time of Rufinamide. Separate 
portions of drug product and ingredients were exposed to 
the following stress conditions to induce degradation. 
Forced degradation studies were performed to evaluate the 
stability indicating properties and specificity of the method 
10
. All solutions for use in stress studies were prepared at 
an initial concentration of 1 mg/mL of Rufinamide and 
refluxed for 30 min at 80 ºC. A ll samples were then diluted 
in mobile phase to give a final concentration of 80 μg/mL 
and filtered before injection.  
Acidic and Alkaline Degradation  
Acid decomposition was carried out in 0.1 M HCl at a  
concentration of 1.0 mg/mL Rufinamide and after 
refluxation for 30 min at 80 ºC the stressed sample was 
cooled, neutralized and diluted with mobile phase to give a 
final concentration of 80 μg/mL and filtered before 
injection.  
Similarly stress studies in alkaline conditions were 
conducted using a concentration of 1.0 mg/mL in 0.1 M 
NaOH and refluxed for 30 min at 80 ºC. After cooling the 
solution was neutralized and diluted with mobile phase to 
give a final concentration of 80 μg/mL and filtered before 
injection.  
Oxidative Degradation  
Solutions for oxidative stress studies were prepared using 
3% H2O2 at a concentration of 1 mg/mL of Rufinamide  
and after refluxat ion for 30 min at 80 ºC on the thermostat 
the sample solution was cooled and diluted with the mobile 
phase to give a final concentration of 80 μg/mL and 
filtered before inject ion.  
Thermal Degradation 
For thermal stress testing, the drug solution (1 mg/mL) 
was heated in thermostat at 80 ºC for 30 min, cooled and 
diluted with the mobile phase to give a final concentration 
of 80 μg/mL and filtered before inject ion.  
Photolytic Degradation 
The drug solution (1 mg/mL) for photo stability testing 
was exposed to UV light for 4 hours UV light chamber 
(365 nm) and diluted with the mobile phase to give a final 
concentration of 80 μg/mL and filtered before inject ion.  
Method Validation  
The method was validated for the following parameters : 
system suitability, linearity, limit of quantitation (LOQ), 
limit of detection (LOD), precision, accuracy, selectivity 
and robustness 
11
. 
Linearity  
Linearity test solutions for the assay method were prepared 
from a stock solution at different concentration levels of 
the analyte (0.01-160 µg/mL). 20 µL of each solution was 
injected in to the HPLC system and the peak area of the 
chromatogram obtained was noted.  
The solutions ext racted from the marketed formulat ions 
were in jected in to the HPLC system and the peak area of 
the chromatograms was noted. The analytical curve was 
evaluated on three different days. The peak area vs. 
concentration data was analyzed with least squares linear 
regression. The slope and y-intercept of the calibration 
curve was reported. 
Precision  
The intra-day precision of the assay method was evaluated 
by carrying out 9 independent assays of a test sample of 
Rufinamide at three concentration levels (20, 40 and 80 
µg/mL) (n=3) against a qualified reference standard. The 
%RSD of three obtained assay values at three different 
concentration levels was calculated. The interday precision 
study was performed on three different days i.e. day 1, day 
2 and day 3 at three different concentration levels (20, 40 
and 80 µg/mL) and each value is the average of three 
determinations (n=3). The % RSD of three obtained assay 
values on three different days was calculated.  
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Accuracy  
The accuracy of the assay method was evaluated in 
triplicate at three concentration levels (80, 100 and 120%), 
and the percentage recoveries were calcu lated. Standard 
addition and recovery experiments were conducted to 
determine the accuracy of the method for the 
quantification of Rufinamide in the drug product. The 
study was carried out in triplicate at 18, 20 and 22 µg/mL. 
The percentage recovery in each case was calculated.  
Sensitivity/Limit of quanti fication (LOQ) and limit of 
detection (LOD)  
The limit of quantification (LOQ) and limit of detection 
(LOD) were based on the standard deviation of the 
response and the slope of the constructed calibration curve 
(n=3), as described in International Conference on 
Harmonizat ion guidelines Q2 (R1) 
11
. Sensitivity of the 
method was established with respect to limit of detection 
(LOD) and LOQ for Rufinamide. LOD and LOQ were 
established by slope method as mentioned below.  
LOD = 
3.3 × standard deviation of y-intercept 
Slope of the calibration curve  
 
LOQ= 
10 × standard deviation of y-intercept 
Slope of the calibration curve  
 
LOD and LOQ were experimentally verified by inject ing 
six replicate injections of each impurity at the 
concentration obtained from the above formula. 
Robustness  
The robustness of the assay method was established by 
introducing small changes in the HPLC conditions which 
included wavelength (208 and 212 nm), percentage of 
acetonitirile in the mobile phase (54 and 50) and flow rate 
(0.9 and 1.1 mL/min). Robustness of the method was 
studied using six rep licates at a concentration level of 20 
µg/mL of Rufinamide.  
Solution Stability and Mobile Phase Stability  
The solution stability of Rufinamide in the assay method 
was carried out by leaving both the sample and reference 
standard solutions in tightly capped volumetric flasks at 
room temperature for 48 h. The same sample solutions 
were assayed at 12 h intervals over the study period. The 
mobile phase stability was also assessed by assaying the 
freshly prepared sample solutions against freshly prepared 
reference standard solutions at 12 h intervals up to 48 h. 
The prepared mobile phase remained constant during the 
study period. The % RSD of the Rufinamide assay was 
calculated for the mobile phase and solution stability 
experiments. An additional study was carried out using the 
stock solution by storing it in a tightly capped volumetric 
flask at 4 ºC. 
RES ULTS AND DISCUSS ION  
No stability indicating method is available in the official 
compendia using HPLC for analysing Rufinamide in  
dosage forms till now. The present proposed method is 
simple, precise and accurate in comparison to the reported 
methods in the literature (Table 1). 
A reversed-phase chromatographic technique was 
developed to quantitate Rufinamide at 210 nm. Methanol 
was chosen as an organic modifier in the mobile phase. 
Satisfactory resolution was achieved with use of a mixture 
of methanol and water (52:48, V/V) as demonstrated in 
Figure 2. C8 and C18 columns were first evaluated as 
stationary phase for the separation of Rufinamide. C18 
column was adopted for the analysis because it provided a 
better separation of the analytes. 
Table 1 Comparison of the performance characteristics of the present method with the published methods  
S. No. Method /Reagent λ  (nm) Linearity (g/mL) Remarks Ref. 
1. HPLC  
(Robotic system) 
 
230 
 
0.05–4.0  
 
Human Plasma  
 
3 
2. HPLC  
Acetonitrile: methanol: potassium 
dihydrogen phosphate  
 
- 
 
0.05-19.09 
Plas ma 
(Liquid-solid extract ion) 
 
 
4 
3 HPLC 
Acetonitrile: methanol : Potassium 
dihydrogen phosphate  
-  
0.05–20 
 
Plas ma and brain  
 
5 
4 HPLC 
Acetonitrile: methanol Potassium 
dihydrogen phosphate buffer (pH 4.5) 
 
210 
 
2-40 
 
Very narrow linearity range 
(UV/v isible detector) 
 
6 
5 HPLC 
Methanol: d ichloromethane:n-hexane  
230  
0.25–20.0  
 
Plas ma and Saliva  
 
7 
6 LC-MS - 0.48–47.6  dried blood spots 8 
7 HPLC 
Methanol: water  
(Adjusted to pH 3.0 with ortho 
phosphoric acid) 
 
220 
 
10-60 
 
Very narrow linearity range 
 
 
9 
8 HPLC 
Methanol:  water 
(52:48, V/V) 
 
210 
 
0.01-160 
Stability indicating method 
Wide linearity range 
(PDA detector) 
 
Present 
work 
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The methods reported in the literature are applicable only  for bioanalytical determination of Rufinamide. The present 
method is a stability indicating RP-HPLC method which was not reported earlier.  
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Figure 2: Typical Chromatogram of Rufinamide (80 μg/mL) 
The present stability-indicat ing method for the 
determination of Rufinamide in pharmaceutical 
formulat ions is specific because the drug peak was well 
separated even in the presence of degradation products. 
Overall, the data demonstrated that the e xcip ients and the 
degradation products did not interfere with the Rufinamide  
peak, indicating the selectivity of the method. The 
complete separation of the analytes was accomplished in 
less than 10 min and the method can be successfully 
applicable to perform long-term and accelerate stability 
studies of Rufinamide formulat ions. 
HPLC Method Development and Optimization  
Initially the stressed samples were analyzed using a mobile 
phase consisting of water: acetonitrile (70:30, v/v) at a 
flow rate of 1.0 mL/min. Under these conditions, the 
resolution and peak symmetry were not satisfactory, so the 
mobile phase was changed to methanol: water (52:48, 
V/V) with a flow rate of 1.0 mL/min
 
under which peaks 
were well resolved with good symmetry and sharpness. 
Therefore, mobile phase containing methanol: water 
(52:48, V/V) was chosen for the best chromatographic 
response for the entire study.  
Method Validation  
System Suitability  
The system suitability test was performed to ensure that 
the complete testing system was  suitable for the intended 
application. The parameters measured were peak area, 
retention time, tailing factor, capacity factor and 
theoretical plates. In all measurements the peak area varied 
less than 2.0%, the average retention time was 5.5 ± 0.05 
minutes. The capacity factor was more than 2, theoretical 
plates were 9873 (more than 2000) and tailing factor was 
1.22 (less than 2) for the Rufinamide peak. The proposed 
method offers high sensitivity and Rufinamide can be 
detected accurately. In all the cases, the Rufinamide peak 
was well separated from the degradation products.  
Linearity  
The calibration curve for Rufinamide was linear over the 
concentration range of 0.01–160 μg/mL. The data for the 
peak area of the drug in corresponds to the concentration 
was treated by linear regression analysis  (Table 2) and the 
regression equation for the calibration curve (Figure 3) 
was found to be y = 112887 x + 35285 with correlat ion 
coefficient of 0.9998.  
 
Figure 3: Calibration Curve of Rufinamide  
Table 2: Linearity of Rufinamide 
 
Precision  
The precision of the method was determined by 
repeatability (Intra-day precision) and intermediate 
precision (Inter-day precision) o f the Rufinamide standard 
solutions. Repeatability was calculated by assaying three 
samples of each at three different concentration levels (20, 
40 and 80 µg/mL) on the same day. The inter-day 
Conc. (μg/mL)  *Mean area ± SD RSD (%) 
0.01 1490.33±5.033 0.34 
0.05 5816.33±15.18 0.26 
0.1 12298.33±25.17 0.21 
0.5 59028.00±136.57 0.23 
1 120509.00±552.39 0.46 
5 584986.00±1660.33 0.28 
10 1183090.33±4199.83 0.35 
20 2362078.66±4904.92 0.21 
40 4554834.66±10664.88 0.23 
80 9026285.00±11646.05 0.29 
100 11437163.66±58773.76 0.51 
120 13771048.00±77113.34 0.56 
160 17849924.00±123972.63 0.69 
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precision was calculated by assaying three samples of each 
at three different concentration levels (20, 40 and 80 
µg/mL) on three different days. The % RSD range was 
obtained as 0.32-0.40 and 0.57-0.64 for intra-day and 
inter-day precision studies respectively (Table 3).  
 
Table 3: Intra-day and inter-day precision studies of Rufinamide  
Sample No. Conc. 
(µg/mL) 
Intra-day precision % RSD* 
 
Inter-day precision % RSD* 
 
Mean* ± SD Mean* ± SD 
1 20 2363967.67 ± 8872.07 0.38 2363353±15026.35 0.64 
2 40 4654783.67 ± 14571.25 0.32 4660375±26331.69 0.57 
3 80 9024309.33±35772.41 0.40 9018740.33±54186.57 0.60 
*Mean of three replicates 
Because the stability of standard solutions can also affect 
the robustness of analytical methods, the stability of 
standard solutions of the drug substance used in this 
method was tested over a long period of time. One portion 
of a standard solution was kept at room temperature and 
the other portion was stored under refrigeration at 
approximately 4ºC and the content of these solutions was 
regularly compared with that of freshly prepared solutions. 
No change in drug concentrations were observed for 
solutions stored under refrigeration. But it is recommended 
that the sample and standard solutions must therefore, be 
freshly prepared in amber colored flasks to protect from 
light. 
Accuracy  
The method accuracy was proven by the recovery test. A 
known amount of Rufinamide standard (10 μg/mL) was 
added to aliquots of samples solutions and then diluted to 
yield total concentrations as 18, 20 and 22 μg/mL as 
described in Table 4. The assay was repeated over 3 
consecutive days. The resultant % RSD was 0.83 (<2.0 %) 
with a recovery 97.20-97.83 %. 
Table 4: Accuracy - recovery study of Rufinamide by standard-addition method 
Sample No. Spiked Conc. (µg/mL) *Measured Conc. (µg/mL) (% ) Recovery* (% ) RSD *  
1 8 (80 %) 7.78 97.25  
0.83 2 10 (100 %) 9.72 97.20 
3 12 (120 %) 11.74 97.83 
*Mean of three replicates 
Limit of Detection and Limit of Quantification 
The LOQ and LOD were determined based on the 10 and 
3.3 times the standard deviation of the response, 
respectively, divided by the slope of the calibration curve. 
The LOQ and LOD were found to be 0.0086 μg/mL and 
0.0028 μg/mL respectively.  
Robustness  
The robustness of an analytical procedure refers to its 
ability to remain unaffected by small and deliberate 
variations in method parameters and provides an indication 
of its reliab ility for routine analysis 
10
. The robustness of 
the method was evaluated by assaying the same sample 
under different analytical conditions deliberately changing 
from the original condition. The detection wavelength was 
set at 208 and 212 nm (± 2 nm), the ratio of percentage of 
methanol: water in the mobile phase was applied as 54:48 
and 50:50 (± 2 %, V/V), the flow rate was set at 0.9 and 
1.1 mL/min (± 0.1 mL/min). The results obtained from 
assay of the test solutions were not affected by varying the 
conditions and were in accordance with the results for 
original conditions. The % RSD value of assay determined 
for the same sample under original conditions and 
robustness conditions was less than 2.0% indicating that 
the developed method was robust.  
Selectivity/Specificity  
The specificity of the developed method was determined 
by injecting sample solutions (80 μg/mL) which were 
prepared by forcibly degrading under such stress 
conditions as heat, light, oxidative agent, acid and base 
under the proposed chromatographic conditions. The 
stability indicating capability of the method was 
established from the separation of Rufinamide peak from 
the degraded samples derived from the software. The 
degradation of Rufinamide was found to be very similar 
for both the tablets and standard.  
Solution Stability and Mobile Phase Stability   
The %RSD of the assay of Rufinamide from the solution 
stability and mobile phase stability experiments was within  
2%. The results of the solution and mobile phase stability 
experiments confirm that the sample solutions and mobile 
phase used during the assays were stable up to 48 h at 
room temperature and up to 3 months at 4ºC.  
Analysis of Commercial Formulations (Tablets)  
The proposed method was applied to the determination of 
Rufinamide tablets 
Pr
BANZEL
™ ® 
 and BANZEL
® 
and the 
result of these assays yielded 96.74- 97.10 % respectively  
with RSD < 2.0 %. The result of the assay (Table 5) 
indicates that the method is selective for the assay of 
Rufinamide without interference from the excipients used 
in these tablets. The typical chromatograms for 
Rufinamide obtained from the ext racted marketed  
formulat ions were shown in Figure 4a and 4b.
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Table 5: Analysis of Rufinamide commercial formulation (Tablets)  
Sample No. Formulation Labeled claim (mg) *Amount found   (mg) *Recovery (% ) 
1 
Pr
BANZEL
™ ®
 400 388.41 97.10 
2 BANZEL
®
 400 386.98 96.74 
*Mean of three replicates  
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Figure 4a: Typical Chromatogram of Rufinamide (80 μg/mL) 
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Figure 4b: Typical Chromatogram of Rufinamide (80 μg/mL) BANZEL
®  
(400 mg) 
Forced Degradation Studies  
Rufinamide standard and tablet powder was found to be quite stable under dry heat conditions. Typical chromatograms 
obtained following the assay of stressed samples are shown in Figure 5a-5e.  
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Figure 5a: Typical Chromatogram of Rufinamide (80 μg/mL) on  Acidic degradation 
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Figure 5b: Typical  Chromatogram of Rufinamide (80 μg/mL) on Alkaline degradation  
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Figure 5c: Typical Chromatogram of Rufinamide (80 μg/ mL) on Oxidative degradation  
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Figure 5d: Typical  Chromatogram of Rufinamide (80 μg/mL) on Photolytic degradation 
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Figure 5e: Typical Chromatogram of Rufinamide (80 μg/mL) on Thermal degradation  
A very slight decomposition was seen on exposure of 
Rufinamide drug solution to acidic (1.36), alkaline (0.58) 
and oxidation (0.81). During the oxidative degradation two 
major degradants were observed at 2.452 mins and 2.784 
mins without interfering the elution of drug peak (5.534 
mins) and the percentage of drug decomposition was found 
to be 0.81 % indicat ing that the drug is highly resistant 
towards oxidation. Rufinamide has undergone thermal 
(0.16) and UV degradation (0.77) very  slightly i.e less than 
1.0 %. Table 6 summarises the data of degradation studies .
 
Table 6: Forced degradation studies of Rufinamide  
Stress Conditions *Drug recovered (% ) *Drug decomposed (% ) 
Standard Drug 100 - 
Acidic Hydrolysis 98.64 1.36 
Alkaline Hydrolysis  99.42 0.58 
Oxidative degradation 99.19 0.81 
Thermal degradation 99.84 0.16 
Photolytic degradation 99.23 0.77 
*Mean of three replicates 
CONCLUS ION 
The proposed stability-indicat ing HPLC method was 
validated as per ICH guidelines and applied for the 
determination of Rufinamide in pharmaceutical dosage 
forms. The method was found to be accurate, precise, 
robust and specific as the drug peak did not interfere with 
the extra peaks aroused during the forced degradation 
studies. At the same time the chromatographic elution step 
is undertaken in a short time (< 6 min). No interference 
from any components of pharmaceutical dosage form or 
degradation products and therefore the method can be 
successfully applied  to perform long-term and accelerated 
stability studies of Rufinamide formulations. In 
conclusion, the high sensitivity, good selectivity, accuracy 
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and reproducibility of the proposed method is suitable for 
quality control analysis of complex pharmaceutical 
preparation containing Rufinamide. The reduction of 
acetonitrile consumption is one of the best solutions to the 
current global acetonitrile  shortage and will safeguard 
against future risk. 
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